Wells Fargo Initiates Coverage On Design Therapeutics with Overweight Rating, Announces Price Target of $26
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Wells Fargo analyst Tianqi Hang initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Overweight rating and announces Price Target of $26.
Wells Fargo analyst Tianqi Hang initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Overweight rating and announces Price Target of $26.